Business

 

Free Research Reports on ABIO, ANX, HEB and ISIS Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit



31.01.2013 16:47:41 -

(live-PR.com) -
NEW YORK, NY -- (Marketwire) -- 01/31/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Arca Biopharma Inc. (NASDAQ: ABIO) principal focus is to develop personalized therapies for the treatment of
cardiovascular disease through the use of genetics. The company was among the biggest movers in the biotech industry Wednesday gaining over 35 percent on nearly 4 million shares traded.





Find out more about Arca Biopharma including full access to the free equity report at: www.BedfordReport.com/ABIO : http://www.bedfordreport.com/ABIO



ADVENTRX Pharmaceuticals, Inc. (NYSE: ANX) shares gained 25 percent on nearly 3 million shares traded Wednesday, which was almost ten-times the average daily volume. The company has initiated patient recruitment in its pivotal phase 3 clinical study of ANX-188 in sickle cell disease.



Find out more about ADVENTRX Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ANX : http://www.bedfordreport.com/ANX



Hemispherx BioPharma, Inc. (NYSE: HEB) shares rallied over 17 percent on almost double the average daily volume Wednesday. The Prescription Drug User Fee Act review goal for the FDA to complete its review of the NDA for Ampligen is February 2, 2013.



Find out more about Hemispherx BioPharma including full access to the free equity report at: www.BedfordReport.com/HEB : http://www.bedfordreport.com/HEB



ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares reached a 4-month high Tuesday gaining over 11 percent on nearly four-times the average daily volume Wednesday. On Wednesday, the U.S. Food and Drug Administration approved the company's new drug application for Kynamro, a treatment for a rare form of high cholesterol.



Find out more about ISIS Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ISIS : http://www.bedfordreport.com/ISIS



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : http://www2.marketwire.com/mw/emailprcntct?id=5455AB370B3AA151



 

Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
refer this article
Print This Article